Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.49 -6.0%	$1.97	$1.11 ▼ $5.00	$705.28M	1.81	1.57 million shs	1.68 million shs
CASI CASI Pharmaceuticals	$1.30 -9.1%	$1.63	$1.09 ▼ $7.67	$17.59M	0.53	48,160 shs	12,174 shs
FRLN Freeline Therapeutics	$6.48	$6.48	$2.11 ▼ $8.74	$28.12M	0.66	12,055 shs	N/A
OPT Opthea	$3.41 +7.2%	$3.41	$2.02 ▼ $6.30	$524.84M	1.17	27,241 shs	3,000 shs
PRTO Proteon Therapeutics	$3.05 -3.5%	$19.37	$0.22 ▼ $3.94	$67.65M	0.6	1.11 million shs	180,841 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-6.04%	+5.51%	+17.45%	+84.44%	-44.04%
CASI CASI Pharmaceuticals	-9.09%	-7.47%	-29.35%	-32.64%	-79.20%
FRLN Freeline Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+63.16%
PRTO Proteon Therapeutics	+3.61%	+12.86%	+0.64%	-24.22%	+33.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5139 of 5 stars	3.5	1.0	0.0	0.0	2.2	3.3	0.6
CASI CASI Pharmaceuticals	4.2313 of 5 stars	3.5	3.0	0.0	4.3	3.8	1.7	0.0
FRLN Freeline Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPT Opthea	0.3863 of 5 stars	1.1	0.0	0.0	0.0	2.7	0.8	0.6
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	274.30% Upside
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	207.69% Upside
FRLN Freeline Therapeutics	0.00	N/A	N/A	N/A
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
PRTO Proteon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AUTL, FRLN, PRTO, OPT, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	65.48	N/A	N/A	$1.61 per share	1.55
CASI CASI Pharmaceuticals	$28.54M	0.56	N/A	N/A	$0.12 per share	10.83
FRLN Freeline Therapeutics	N/A	N/A	N/A	N/A	$12.07 per share	N/A
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
FRLN Freeline Therapeutics	-$88.97M	-$5.59	N/A	N/A	N/A	N/A	-150.46%	-97.01%	N/A
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
PRTO Proteon Therapeutics	-$20.73M	-$1.15	N/A	N/A	N/A	N/A	N/A	-118.68%	N/A

Latest AUTL, FRLN, PRTO, OPT, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FRLN Freeline Therapeutics	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
CASI CASI Pharmaceuticals	N/A	0.81	0.68
FRLN Freeline Therapeutics	N/A	1.95	N/A
OPT Opthea	N/A	1.57	N/A
PRTO Proteon Therapeutics	N/A	5.98	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
CASI CASI Pharmaceuticals	22.23%
FRLN Freeline Therapeutics	46.26%
OPT Opthea	55.95%
PRTO Proteon Therapeutics	23.03%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
CASI CASI Pharmaceuticals	21.24%
FRLN Freeline Therapeutics	1.90%
OPT Opthea	3.20%
PRTO Proteon Therapeutics	45.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
FRLN Freeline Therapeutics	152	4.34 million	4.26 million	Not Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
PRTO Proteon Therapeutics	17	22.18 million	N/A	Not Optionable

AUTL, FRLN, PRTO, OPT, and CASI Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan

November 9, 2024 | markets.businessinsider.com

Protara Therapeutics (TARA) Earnings Dates & Reports

November 1, 2024 | investing.com

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

October 29, 2024 | markets.businessinsider.com

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

October 28, 2024 | msn.com

ProQR Announces Major Share Offering Agreement

October 25, 2024 | markets.businessinsider.com

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

October 22, 2024 | msn.com

Understanding Neurodegenerative Disease with Prion Research

September 13, 2024 | the-scientist.comT

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

September 11, 2024 | msn.com

iPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to Expect

September 8, 2024 | macrumors.comM

PS5 Pro: the latest on rumored specs, price, and release date speculation

August 30, 2024 | techradar.comT

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

May 22, 2024 | seekingalpha.com

PTC Therapeutics: Q1 Earnings Snapshot

April 25, 2024 | timesunion.comT

Protara Therapeutics Inc (TARA)

April 24, 2024 | investing.com

iPad Pro

February 2, 2024 | macrumors.comM

Esperion Therapeutics Inc ESPR

November 5, 2023 | morningstar.comM

The Latest Analyst Ratings for Revance Therapeutics

September 20, 2023 | benzinga.com

ENLV - Enlivex Therapeutics Ltd.

June 6, 2023 | finance.yahoo.com

Prelude Therapeutics Insider Trades Send a Signal

May 25, 2023 | benzinga.com

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth

May 22, 2023 | benzinga.com

The best iPhone 14 Pro deals for May 2023

May 18, 2023 | techradar.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
Reddit Stock Ignites: Surge in Call Options Signals Big Bet
By Gabriel Osorio-Mazilli | June 24, 2025
View Reddit Stock Ignites: Surge in Call Options Signals Big Bet
Snowflake Hits 52-Week High—Options Traders Bet on Further Rally
By Gabriel Osorio-Mazilli | June 29, 2025
View Snowflake Hits 52-Week High—Options Traders Bet on Further Rally

AUTL, FRLN, PRTO, OPT, and CASI Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.49 -0.16 (-6.04%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.53 +0.04 (+1.77%)

As of 07/15/2025 07:57 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

CASI Pharmaceuticals NASDAQ:CASI

$1.30 -0.13 (-9.09%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.00 (+0.31%)

As of 07:04 AM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Freeline Therapeutics NASDAQ:FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 07/14/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Proteon Therapeutics NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time